JP2008531704A - ウイルス感染症の治療のための三環式ヌクレオシド化合物 - Google Patents

ウイルス感染症の治療のための三環式ヌクレオシド化合物 Download PDF

Info

Publication number
JP2008531704A
JP2008531704A JP2007558142A JP2007558142A JP2008531704A JP 2008531704 A JP2008531704 A JP 2008531704A JP 2007558142 A JP2007558142 A JP 2007558142A JP 2007558142 A JP2007558142 A JP 2007558142A JP 2008531704 A JP2008531704 A JP 2008531704A
Authority
JP
Japan
Prior art keywords
methyl
ribofuranosyl
benzo
dihydro
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007558142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531704A5 (enExample
Inventor
ジェシー ディー. ケイチャー
クリストファー ドン ロバーツ
セバスチャン ヨハネス ラインハルト リアー
シャオリン チェン
マリヤ プルハブク
ヴィヴェック クマール ラジュワンシ
ロナルド コンラッド グリフィス
チョン ユー. キム
Original Assignee
ジェネラブズ テクノロジーズ インコーポレーティッド
ギリード サイエンシズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネラブズ テクノロジーズ インコーポレーティッド, ギリード サイエンシズ インコーポレーティッド filed Critical ジェネラブズ テクノロジーズ インコーポレーティッド
Publication of JP2008531704A publication Critical patent/JP2008531704A/ja
Publication of JP2008531704A5 publication Critical patent/JP2008531704A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22Pteridine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007558142A 2005-02-28 2006-02-28 ウイルス感染症の治療のための三環式ヌクレオシド化合物 Withdrawn JP2008531704A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65746305P 2005-02-28 2005-02-28
PCT/US2006/007132 WO2006093987A1 (en) 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections

Publications (2)

Publication Number Publication Date
JP2008531704A true JP2008531704A (ja) 2008-08-14
JP2008531704A5 JP2008531704A5 (enExample) 2009-04-09

Family

ID=36570903

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007558142A Withdrawn JP2008531704A (ja) 2005-02-28 2006-02-28 ウイルス感染症の治療のための三環式ヌクレオシド化合物
JP2007558141A Withdrawn JP2008531703A (ja) 2005-02-28 2006-02-28 ウイルス感染症の治療のための三環式ヌクレオシドプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007558141A Withdrawn JP2008531703A (ja) 2005-02-28 2006-02-28 ウイルス感染症の治療のための三環式ヌクレオシドプロドラッグ

Country Status (18)

Country Link
US (4) US7534771B2 (enExample)
EP (2) EP1853617A1 (enExample)
JP (2) JP2008531704A (enExample)
KR (2) KR20070106781A (enExample)
CN (2) CN101142226A (enExample)
AP (2) AP2007004118A0 (enExample)
AR (1) AR058419A1 (enExample)
AU (2) AU2006218705A1 (enExample)
BR (2) BRPI0607770A2 (enExample)
CA (2) CA2597685A1 (enExample)
EA (2) EA200701849A1 (enExample)
HR (2) HRP20070436A2 (enExample)
IL (2) IL184955A0 (enExample)
MX (2) MX2007010463A (enExample)
NO (2) NO20074613L (enExample)
TW (1) TW200640474A (enExample)
WO (2) WO2006093986A1 (enExample)
ZA (1) ZA200707410B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514772A (ja) * 2012-04-18 2015-05-21 バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. ウイルスポリメラーゼを阻害するための組成物および方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486883T1 (de) * 2003-08-27 2010-11-15 Biota Scient Management Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
CN101142226A (zh) * 2005-02-28 2008-03-12 健亚生物科技公司 用于治疗病毒感染的三环核苷化合物
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008106166A2 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
GB0718575D0 (en) * 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
KR101620394B1 (ko) * 2008-04-03 2016-05-12 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
KR20110099138A (ko) 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
GB0900914D0 (en) * 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
AU2010232647A1 (en) * 2009-03-31 2011-10-20 Arqule, Inc. Peri-fused pyrazolo-pyrimidine compounds
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL2552930T3 (pl) 2010-03-31 2016-02-29 Gilead Pharmasset Llc Krystaliczny 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1-(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian (S)-izopropylu
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
CA2795054A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20140113958A1 (en) 2011-06-30 2014-04-24 Stella Aps HCV Combination Therapy
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
ME03009B (me) 2011-09-16 2018-10-20 Gilead Pharmasset Llc Metode za lecenje hcv-a
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2639238A1 (en) * 2012-03-15 2013-09-18 Universität Bern Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのd−アミノ酸化合物
PL2861611T3 (pl) 2012-05-25 2017-08-31 Janssen Sciences Ireland Uc Nukleozydy uracylowe spirooksetanu
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
UA118256C2 (uk) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Комбінований склад двох противірусних сполук
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US20150064253A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
IE911129A1 (en) 1990-04-04 1991-10-09 Chiron Corp Hepatitis c virus protease
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5738985A (en) 1993-04-02 1998-04-14 Ribogene, Inc. Method for selective inactivation of viral replication
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
JP4191797B2 (ja) 1995-09-27 2008-12-03 エモリー ユニバーシティー 組み換えc型肝炎ウイルスrnaレプリカーゼ
US5759795A (en) 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
PL335721A1 (en) 1997-03-05 2000-05-08 Ribogene Novel methods of screening serving the purpose of identifying the factors of selective hepatitis c virus replication inhibition
WO1998043991A1 (en) 1997-04-02 1998-10-08 Amersham Pharmacia Biotech Uk Limited Tricyclic base analogues
CA2312484A1 (en) 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
WO2003061385A1 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
WO2004014313A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
ATE486883T1 (de) * 2003-08-27 2010-11-15 Biota Scient Management Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
US7151089B2 (en) 2003-10-27 2006-12-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
KR20060096487A (ko) * 2003-10-27 2006-09-11 진랩스 테크놀러지스, 인크. 바이러스 감염증들을 치료하기 위한 뉴클레오시드 화합물
CN101142226A (zh) 2005-02-28 2008-03-12 健亚生物科技公司 用于治疗病毒感染的三环核苷化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514772A (ja) * 2012-04-18 2015-05-21 バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. ウイルスポリメラーゼを阻害するための組成物および方法

Also Published As

Publication number Publication date
HRP20070435A2 (hr) 2008-02-29
AP2007004128A0 (en) 2007-08-31
TW200640474A (en) 2006-12-01
CA2597683A1 (en) 2006-09-08
AR058419A1 (es) 2008-02-06
US20090208457A1 (en) 2009-08-20
US7534771B2 (en) 2009-05-19
IL184955A0 (en) 2007-12-03
NO20074613L (no) 2007-11-27
CA2597685A1 (en) 2006-09-08
HRP20070436A2 (hr) 2008-02-29
MX2007010460A (es) 2007-11-08
KR20070106781A (ko) 2007-11-05
CN101128474A (zh) 2008-02-20
BRPI0607769A2 (pt) 2009-10-06
US20060194749A1 (en) 2006-08-31
BRPI0607770A2 (pt) 2009-06-13
AU2006218705A1 (en) 2006-09-08
ZA200707410B (en) 2008-10-29
AP2007004118A0 (en) 2007-08-31
NO20074915L (no) 2007-11-20
WO2006093986A1 (en) 2006-09-08
HRP20070435A9 (en) 2008-09-30
US7524825B2 (en) 2009-04-28
KR20070106767A (ko) 2007-11-05
IL184954A0 (en) 2007-12-03
WO2006093987A1 (en) 2006-09-08
JP2008531703A (ja) 2008-08-14
EA200701850A1 (ru) 2008-02-28
AU2006218704A1 (en) 2006-09-08
EA200701849A1 (ru) 2008-02-28
US20090253648A1 (en) 2009-10-08
EP1853618A1 (en) 2007-11-14
US20060252715A1 (en) 2006-11-09
EP1853617A1 (en) 2007-11-14
MX2007010463A (es) 2007-11-08
CN101142226A (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
US7524825B2 (en) Tricyclic-nucleoside compounds for treating viral infections
US20090048189A1 (en) Tricyclic-nucleoside compounds for treating viral infections
US7405204B2 (en) Nucleoside compounds for treating viral infections
US7157434B2 (en) Nucleoside compounds for treating viral infections
US7144868B2 (en) Nucleoside compounds for treating viral infections
US7244713B2 (en) Nucleoside compounds for treating viral infections
US7414031B2 (en) 5-nitro-nucleoside compounds for treating viral infections
US7202223B2 (en) Nucleoside compounds for treating viral infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090218

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091023

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091023